These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 7648282)

  • 1. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.
    Biron F; Lucht F; Peyramond D; Fresard A; Vallet T; Nugier F; Grange J; Malley S; Hamedi-Sangsari F; Vila J
    J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):36-40. PubMed ID: 7648282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
    Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
    Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
    Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
    Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
    Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
    Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydroxychloroquine, hydroxyurea and didanosine as initial therapy for HIV-infected patients with low viral load: safety, efficacy and resistance profile after 144 weeks.
    Paton NI; Aboulhab J
    HIV Med; 2005 Jan; 6(1):13-20. PubMed ID: 15670247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
    Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
    J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3.
    Ibáñez A; Peraire J; Arnó A; Gutiérrez C; Cervantes M; Colomer J; Villalonga C; Camafort M; Ruiz L; Balaguer M; Vidal F; Richart C; Clotet B
    Antivir Ther; 1997 Apr; 2(2):105-11. PubMed ID: 11322274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxyurea toxicity combined with didanosine (ddl) in HIV-1-seropositive asymptomatic individuals.
    Seminari E; Lisziewicz J; Tinelli C; Foli A; Lori F; Maserati R
    Int J Clin Pharmacol Ther; 1999 Oct; 37(10):514-8. PubMed ID: 10543320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of once and twice daily dosing of didanosine in combination with stavudine for the treatment of HIV-1 infection. AI 454-146 Team.
    Monno L; Cargnel A; Soranzo ML; Chirianni A; Ferraro T; Di Stefano M; Angarano G
    Antivir Ther; 1999; 4(4):195-202. PubMed ID: 10723498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
    Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
    Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
    Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
    Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trial.
    Molina JM; Marcelin AG; Pavie J; Heripret L; De Boever CM; Troccaz M; Leleu G; Calvez V;
    J Infect Dis; 2005 Mar; 191(6):840-7. PubMed ID: 15717257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Once-daily administration of didanosine in combination with anti-retroviral zidovudine in previously untreated patients].
    Reynes J; Montes B; Delmas B; Vendrell JP; Janbon F; Segondy M
    Pathol Biol (Paris); 1997 May; 45(5):441-4. PubMed ID: 9296101
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized trial to investigate the recycling of stavudine and didanosine with and without hydroxyurea in salvage therapy (RESTART).
    Stebbing J; Nelson M; Orkin C; Mandalia S; Bower M; Pozniak A; Gazzard B
    J Antimicrob Chemother; 2004 Mar; 53(3):501-5. PubMed ID: 14762056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of once-daily combination therapy with didanosine, lamivudine and nevirapine in antiretroviral-naive HIV-infected patients.
    Ribera E; Rodríguez-Pardo D; Rubio M; Soler A; Pedrol E; Blanco JL; González A; Crespo M; Falcó V; Ocaña I; Deig E; Miró JM; Pahissa A
    Antivir Ther; 2005; 10(5):605-14. PubMed ID: 16152754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A pilot study of a combination of three reverse transcriptase inhibitors in HIV-1 infection.
    Lafeuillade A; Poggi C; Djediouane A; Chollet L; Profizi N; Sayada C
    Antivir Ther; 1997 Dec; 2(4):219-27. PubMed ID: 11327441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue.
    Mathé G; Pontiggia P; Orbach-Arbouys S; Triana K; Ambetima N; Morette C; Hallard M; Blanquet D
    Biomed Pharmacother; 1996; 50(5):220-7. PubMed ID: 8949403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
    Montaner JS; Zala C; Conway B; Raboud J; Patenaude P; Rae S; O'Shaughnessy MV; Schechter MT
    J Infect Dis; 1997 Apr; 175(4):801-6. PubMed ID: 9086133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cell-associated HIV-1 RNA in blood as indicator of virus load in lymph nodes. The Swiss HIV Cohort Study.
    Yerly S; Rutschmann OT; Opravil M; Marchal F; Hirschel B; Perrin L
    J Infect Dis; 1999 Sep; 180(3):850-3. PubMed ID: 10438378
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hydroxyrea and ddI: French study published.
    James JS
    AIDS Treat News; 1995 Sep; (no 230):6. PubMed ID: 11362759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.